An automated, high‐throughput method for targeted quantification of intact insulin and its therapeutic analogs in human serum or plasma coupling mass spectrometric immunoassay with high resolution and accurate mass detection (MSIA‐HR/AM)

Peterman, Scott; Niederkofler, Eric E.; Phillips, David A.; Krastins, Bryan; Kiernan, Urban A.; Tubbs, Kemmons A.; Nedelkov, Dobrin; Prakash, Amol; Vogelsang, Maryann S.; Schoeder, Tara; Couchman, Lewis; Taylor, David R.; Moniz, C.; Vadali, Gouri; Byram, Gregory; Lopez, Mary F.

doi:10.1002/pmic.201300300

Cited by 57 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(see table 1). The mass spectrometry was carried out using a modified version of a previously described method (details provided in (13) and online supplementary methods).…”

Section: Assaysmentioning

confidence: 99%

Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues

Parfitt

Church

Armston

et al. 2015

Clinical Biochemistry

View full text Add to dashboard Cite

“…(see table 1). The mass spectrometry was carried out using a modified version of a previously described method (details provided in (13) and online supplementary methods).…”

Section: Assaysmentioning

confidence: 99%

Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues

Parfitt

Church

Armston

et al. 2015

Clinical Biochemistry

View full text Add to dashboard Cite

“…Currently, only a limited number of MS-based methodologies are amenable of multiplex protein analyses, including MSIA [39] and selected peptide-based proteomics approaches [40–42]. In this work we demonstrate a multiplex MSIA for the apoC-I, apoC-II, apoC-III and their proteoforms.…”

Section: Resultsmentioning

confidence: 99%

Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms

Trenchevska

Schaab

Nelson

et al. 2015

Methods

Self Cite

View full text Add to dashboard Cite

The impetus for discovery and evaluation of protein biomarkers has been accelerated by recent development of advanced technologies for rapid and broad proteome analyses. Mass spectrometry (MS)-based protein assays hold great potential for in vitro biomarker studies. Described here is the development of a multiplex Mass Spectrometric Immunoassay (MSIA) for quantification of apolipoprotein C-I (apoC-I), apolipoprotein C-II (apoC-II), apolipoprotein C-III (apoC-III) and their proteoforms. The multiplex MSIA assay was fast (~40 min) and high-throughput (96 samples at a time). The assay was applied to a small cohort of human plasma samples, revealing the existence of multiple proteoforms for each apolipoprotein C. The quantitative aspect of the assay enabled determination of the concentration for each proteoform individually. Low-abundance proteoforms, such as fucosylated apoC-III, were detected in less than 20% of the samples. The distribution of apoC-III proteoforms varied among samples with similar total apoC-III concentrations. The multiplex analysis of the three apolipoproteins C and their proteoforms using quantitative MSIA represents a significant step forward toward better understanding of their physiological roles in health and disease.

show abstract

“…To address this researchers are typically using affinity chromatography to deplete high abundance proteins and/or enrich for the lower abundance proteins or peptides of interest. One such approach which combines some of the best elements of immunoassay with LC-MS is known as Mass Spectrometric Immunoassay (MSIA™) [24,25] which offers automatable, analytical affinity purification to capture and enrich low abundance proteins followed by elution for analysis by mass spectrometry. This represents a solution that could be implemented now to help adoption of LC-MS until the technology advances sufficiently to remove the requirement for this immuno-enrichment step.…”

Section: Will Lc/lc-ms Ever Replace Immunoassays?mentioning

confidence: 99%

Can LC and LC-MS ever replace immunoassays?

Cross¹,

Hornshaw²

2016

J Appl Bioanal

View full text Add to dashboard Cite

IntroductionThis review is not intended as a summary of research and development of immunoassays and liquid chromatography-mass spectrometry but rather as a brief summary of the pros and cons of each technology applied to the quantitative measurement of biomolecules primarily in biofluids. The ability to detect and quantitate biomolecules revolutionised science in the twentieth century and continues to this day. It allows scientists, for example, to conduct research to find and validate biomarkers, but has found its most prominent role in diagnostic applications where it is used to monitor the presence and levels of biomolecules in human samples for the diagnosis and monitoring of disease, in food and beverages to ensure food safety and authenticity and in the environment to monitor the presence and levels of contaminants of ground, waste and drinking water. The growth in personalised or precision medicine will be accompanied by an increased need to detect and quantify panels of biomolecules as biomarkers, as well as a range of drugs taken as treatment or as a measure to delay or prevent onset of disease, following the paradigm of the right drug for the right patient at the right time and importantly at the right dose. Increased health and safety regulations demand more testing of food and beverage and environmental samples. With increasing need for biomolecule detection and quantitation comes the demand for high-throughput, lower cost per sample analysis and more accurate results. Traditionally, immunoassays have been the technology of choice for the detection and quantitation of biomolecules. However, over the past two decades alternative technologies have been shown to offer a complementary role to immunoassays. Liquid chromatography-mass spectrometry (LC-MS) is one such technology and for some applications has been shown to offer a powerful alternative to immunoassays. With the increasing demands for routine biomolecule quantitation coming from a broad range of fields, are immunoassays the best solution to keep pace with the increased throughput needed, demand for lower cost per sample and improved accuracy Immunoassays have been the technology of choice for the analysis of biomolecules for many decades across a wide range of applications in research, diagnostics and infectious disease monitoring. There are good reasons for the wide adoption of immunoassays but even such a well established and characterised technique has limitations and as such investigators are looking at alternative technologies. One such alternative is liquid chromatography (LC) and, more specifically, liquid chromatography coupled with mass spectrometry (LC-MS). This article will review both immunoassay and LC and LC-MS technologies and methodologies and discuss the advantages and limitations of both approaches. In addition, the next developments that will need to occur before there is widespread adoption of LC and LC-MS technology preferentially over immunoassays will be examined.

show abstract

An automated, high‐throughput method for targeted quantification of intact insulin and its therapeutic analogs in human serum or plasma coupling mass spectrometric immunoassay with high resolution and accurate mass detection (MSIA‐HR/AM)

Cited by 57 publications

References 17 publications

Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues

Commercial insulin immunoassays fail to detect commonly prescribed insulin analogues

Development of multiplex mass spectrometric immunoassay for detection and quantification of apolipoproteins C-I, C-II, C-III and their proteoforms

Can LC and LC-MS ever replace immunoassays?

Contact Info

Product

Resources

About